Asset profile
Mezagitamab
Monoclonal antibody
Evidence outlook · no controlled comparison
NCT03439280 · Relapsed/Refractory, Multiple Myeloma
The lead study is single-arm or otherwise uncontrolled, so it produced no formal comparison against a control. This tier describes the design, not an outcome.
NCT03439280: This was a nonrandomized, open-label, single-arm dose-escalation study of 50 participants, with no placebo or active comparator. Its primary outcomes focused on safety, including treatment-emergent adverse events and dose-limiting toxicities, rather than a controlled efficacy comparison; 50 of 50 participants reported at least one treatment-emergent adverse event, and 1 of 41 dose-limiting-toxicity-evaluable participants had a dose-limiting toxicity.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
73 competitors in this universe: 13 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 23 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Mezagitamab: this drug | Phase 3 | Monoclonal antibody | CD38 | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 | ||
| BCD-264 | Phase 3 | Monoclonal antibody | CD38 | ||
| CT-P44 | Phase 3 | Monoclonal antibody | CD38 | ||
| HLX15 | Phase 3 | Monoclonal antibody | CD38 | ||
| QL2109 | Phase 3 | Monoclonal antibody | CD38 | ||
| SCTC21C | Phase 3 | Biologic (subtype unspecified) | CD38 | ||
| SG301 | Phase 3 | Monoclonal antibody | CD38 | ||
| TJ202 | Phase 3 | Monoclonal antibody | CD38 | ||
| CID-103 | Phase 1/2 | Monoclonal antibody | CD38 | ||
| CM313 | Phase 1/2 | Monoclonal antibody | CD38 | ||
| STI-6129 | Phase 1/2 | Antibody–drug conjugate | CD38 | ||
| SAR442085 | Phase 1 | Biologic (subtype unspecified) | CD38 | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome |
…and 58 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
7 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (2)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.